Advertisement

Role of large unstained cells in predicting successful stem cell collection in autologous stem cell transplantation

      Highlights

      • LUC count and percentage were correlated with preapheresis peripheral CD34 + cells.
      • LUC percentage correlated with collected CD34 + cells.
      • LUCs may be an indicator of graft composition.

      Abstract

      Introduction

      Sufficient stem cell collection is mandatory for Autologous stem cell transplantation (ASCT). Peripheral CD34+ stem CD34 + stem cell counting by flow cytometry is the gold standard method in both the predicting and timing of successful stem cell collection. Large unstained cells (LUC) are large peroxidase-negative cells that are displayed on certain automatic cell counters and present large lymphocytes, virocytes, blasts, abnormal cells and hematopoietic stem cells. In this study, we evaluated the role of LUC parameters in the timing and prediction of successful stem cell collection.

      Methods

      Patients with a diagnosis of multiple myeloma, lymphoma and testis tumor who proceed to ASCT were included in this study. Preapheresis LUC parameters were analyzed with Siemens ADVIA® 2120i system., Kruskal Wallis, Mann-Whitney U, Spearman Rho and receiver–operator curve (ROC) tests were used for analyses.

      Results

      Ninety patients were evaluated. Peripheral CD34 + cell count was positively correlated with both LUC count (p = 0014) and LUC percentage (p = 0,01). LUC percentage in peripheral blood was positively correlated with mobilized stem cell count in the yield (p = 0.003). We found a LUC count of > 0.485 × 109/L as a cut-off value for detecting > 20 × 106/L CD34 +cells in the peripheral blood with a sensitivity of 64.6% and specificity of 75%. We defined > 2.15% as a cut-off value for LUC percentage to collect > 5 × 106/kg of stem cells with a sensitivity of 64% and specificity of 63%. Additionally, total nucleated cell (TNC) count was negatively correlated with LUC percentage (p = 0.014) and positively correlated with LUC count (p = 0.001).

      Conclusion

      LUC parameters are readily available, simple and cheap tools that can be useful in both timing of CD34 count by flow cytometry in peripheral blood and in the prediction of successful mobilization. LUCs can also be an indicator of graft composition.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Philip T.
        • Guglielmi C.
        • Hagenbeek A.
        • Somers R.
        • Van der Lelie H.
        • Bron D.
        • et al.
        Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
        N Engl J Med. 1995; 333: 1540-1545
        • Attal M.
        • Harousseau J.L.
        • Stoppa A.M.
        • Sotto J.J.
        • Fuzibet J.G.
        • Rossi J.F.
        • et al.
        A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome.
        N Engl J Med. 1996; 335: 91-97
        • Gertz M.A.
        review: current status of stem cell mobilization.
        Br J Haematol. 2010; 150: 647-662
        • Hübel K.
        Mobilization and collection of HSC.
        in: Carreras CD Enric Mohty Mohamad Kröger Nicolaus The EBMT handbook. Springer, Switzerland2019: 117-122
        • Mohty M.
        • Hübel K.
        • Kröger N.
        • Aljurf M.
        • Apperley J.
        • Basak G.W.
        • et al.
        Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.
        Bone Marrow Transpl. 2014; 49: 865-872
        • Stiff P.J.
        • Micallef I.
        • Nademanee A.P.
        • Stadtmauer E.A.
        • Maziarz R.T.
        • Bolwell B.J.
        • et al.
        Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
        Biol Blood Marrow Transpl. 2011; 17: 1146-1153
        • Mohle R.
        • Murea S.
        • Pforsich M.
        • Witt B.
        • Haas R.
        Estimation of the progenitor cell yield in a leukapheresis product by previous measurement of CD34+ cells in the peripheral blood.
        Vox Sang. 1996; 71: 90-96
        • Benjamin R.J.
        • Linsley L.
        • Fountain D.
        • Churchill W.H.
        • Sieff C.
        • Cannon M.E.
        • et al.
        Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield.
        Transfusion. 1997; 37: 79-85
        • Turunen A.
        • Silvennoinen R.
        • Partanen A.
        • Valtola J.
        • Siitonen T.
        • Putkonen M.
        • et al.
        Autograft cellular composition and outcome in myeloma patients: results of the prospective multicenter GOA study.
        Transfusion. 2021; 61: 1830-1844
        • Partanen A.
        • Turunen A.
        • Valtola J.
        • Pyörälä M.
        • Vasala K.
        • Kuittinen O.
        • et al.
        Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: results from the prospective multicenter GOA study.
        Transfusion. 2021; 61: 516-525
        • Khera N.
        • Jinneman J.
        • Storer B.E.
        • Heimfeld S.
        • O’Meara M.M.
        • Chauncey T.R.
        • et al.
        Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.
        Biol Blood Marrow Transpl. 2012; 18: 220-228
        • Barker J.N.
        • Scaradavou A.
        • Stevens C.E.
        Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies.
        Blood. 2010; 115: 1843-1849
      1. Kupeli S, Inan G, Ozkan A, Sezgin G, Bayram I, Tanyeli A. Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34+, CD3+, or total mononuclear cell count. n/a.

        • Paul S.M.
        • Shuli L.
        • Sarah N.
        • Edwin P.A.
        • Joseph H.A.
        • Philippe A.
        • et al.
        Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.
        Haematologica. 2016; 101: 499-505
        • Thirup P.
        LUC, what is that? Large unstained cells.
        Clin Chem. 1999; 45: 1100
        • Vanker N.
        • Ipp H.
        Large unstained cells: a potentially valuable parameter in the assessment of immune activation levels in HIV infection.
        Acta Haematol. 2014; 131: 208-212
        • Shin D.
        • Lee M.S.
        • Kim do Y.
        • Lee M.G.
        • Kim D.S.
        Increased large unstained cells value in varicella patients: a valuable parameter to aid rapid diagnosis of varicella infection.
        J Dermatol. 2015; 42: 795-799
        • Bononi A.
        • Lanza F.
        • Dabusti M.
        • Gusella M.
        • Gilli G.
        • Menon D.
        • et al.
        Increased myeloperoxidase index and large unstained cell values can predict the neutropenia phase of cancer patients treated with standard dose chemotherapy.
        Cytometry. 2001; 46: 92-97
        • Jang M.J.
        • Choi H.W.
        • Lee S.Y.
        • Lee O.J.
        • Kim H.R.
        • Shin J.H.
        • et al.
        Application of bone marrow samples for discrimination of acute promyelocytic leukemia from other types of acute leukemia using the routine automated hematology analyzer.
        Int J Lab Hematol. 2014; 36: 531-540
        • Vanker N.
        • Ipp H.
        Large unstained cells: a potentially valuable parameter in the assessment of immune activation levels in HIV infection.
        Acta Haematol. 2014; 131: 208-212
        • Strobl H.
        • Takimoto M.
        • Majdic O.
        • Fritsch G.
        • Scheinecker C.
        • Höcker P.
        • et al.
        Myeloperoxidase expression in CD34+ normal human hematopoietic cells.
        Blood. 1993; 82: 2069-2078
        • Rabizadeh E.
        • Pickholtz I.
        • Barak M.
        • Isakov E.
        • Zimra Y.
        • Froom P.
        Acute leukemia detection rate by automated blood count parameters and peripheral smear review.
        Int J Lab Hematol. 2015; 37: 44-49
        • Tanaka H.
        • Ishii A.
        • Sugita Y.
        • Shimizu R.
        • Sato F.
        • Sakuma Y.
        • et al.
        Impact of hematopoietic progenitor cell count as an indicator for optimal timing of peripheral stem cell harvest in clinical practice.
        J Clin Exp Hematop JCEH. 2017; 56: 150-159
        • Teipel R.
        • Schetelig J.
        • Kramer M.
        • Schmidt H.
        • Schmidt A.H.
        • Thiede C.
        • et al.
        Prediction of hematopoietic stem cell yield after mobilization with granulocyte–colony-stimulating factor in healthy unrelated donors. 2015; 55: 2855-2863
        • Shaughnessy P.
        • Islas-Ohlmayer M.
        • Murphy J.
        • Hougham M.
        • MacPherson J.
        • Winkler K.
        • et al.
        Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
        Biol Blood Marrow Transplant. 2011; 17: 729-736